International Stem Cell Corp (ISCO) Stock Price & Analysis
International Stem Cell Corp (ISCO) rose 10.71% to USD 0.31 as of July 25, 2026 at 05:37 UTC, according to Nexqual real-time market data.
ISCO last closed at USD 0.28; the session ranged USD 0.29–0.32 on volume of 24,000 shares. Market capitalization is $2.48M, with a 52-week range of USD 0.12–0.32 (OQB). Source: Nexqual, July 25, 2026 at 05:37 UTC.
Key Statistics (as of July 25, 2026 at 05:37 UTC)
| Price | USD 0.31 |
|---|---|
| Change | ▲ 10.71% (up) |
| Previous Close | USD 0.28 |
| Open | USD 0.3 |
| Day Range | USD 0.29 – 0.32 |
| 52-Week Range | USD 0.12 – 0.32 |
| Volume | 24,000 shares |
| Market Cap | $2.48M |
| Exchange | OQB |
Technical Analysis (ISCO)
Nexqual's technical model rates ISCO "BUY" based on 5 bullish and 3 bearish signals across 125 daily candles, as of July 25, 2026 at 05:37 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 73.91 (overbought) |
| vs SMA50 | Above (USD 0.18) |
| MACD | 0.02 (positive) |
Analyst Ratings (ISCO)
Wall Street analysts rate ISCO "None", per Nexqual as of July 25, 2026 at 05:37 UTC.
| Consensus Rating | None |
|---|
Earnings (ISCO)
Source: Nexqual, July 25, 2026 at 05:37 UTC.
Financials & Fundamentals (ISCO)
| Total Revenue | $9.29M |
|---|---|
| Revenue Growth (YoY) | +8.70% |
| Gross Margin | +56.98% |
| Operating Margin | -8.21% |
| Profit Margin | -4.11% |
| ROE | -256.38% |
| Debt / Equity | 4,190.48 |
| Current Ratio | 0.76 |
| Total Cash | $933,000 |
| Total Debt | $3.52M |
| Free Cash Flow | $-142,875 |
Source: Nexqual, July 25, 2026 at 05:37 UTC.
Financial Health Score (ISCO)
Nexqual rates International Stem Cell Corp's overall financial health "Critical" across five dimensions, as of July 25, 2026 at 05:37 UTC.
| Growth | Critical — Revenue -15% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Critical — $933K cash vs $4M debt |
| Cash Flow | Weak — FCF negative: -$143K, burning cash |
| Efficiency | Critical — ROE -256%, ROA -2.8% |
Ownership (ISCO)
| Insider Ownership | +53.77% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 8.00M |
| Float | 3.70M |
Source: Nexqual, July 25, 2026 at 05:37 UTC.
Leadership (ISCO)
International Stem Cell Corp is led by Andrey Semechkin (age 65), Co-Chairman of the Board & CEO, per Nexqual as of July 25, 2026 at 05:37 UTC.
| Co-Chairman of the Board & CEO | Andrey Semechkin (age 65) |
|---|---|
| Executive VP, Chief Scientific Officer, Principal Financial Officer & Director | Russell Kern (age 39) |
| President of Lifeline Cell Technology | Rebecca McGee |
From International Stem Cell Corp's Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally.
- It develops ISC-hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson's disease, as well as for treating stroke, traumatic brain injury, and Alzheimer's disease.
- The company offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, ProPlus Eye Firming Complex, ProPlus Neck Firming Complex, ProPlus Advanced Aqueous Treatment, ProPlus Collagen Booster, ProPlus Elastin Booster, and ProPlus Brightening Toner.
- In addition, it provides human cell culture products comprising human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BTIM | BOATIM INC | USD 0 | ▲ 0% |
| BTX | BlackRock Technology and Privat | USD 8.2 | ▼ 2.73% |
| MCET | MULTICELL TECHNOLOGIES INC | USD 0 | ▲ 0% |
| CCEL | Cryo-Cell International, Inc. | USD 3.46 | ▼ 2.26% |
| NNVC | NanoViricides, Inc. | USD 1.48 | ▼ 2.63% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 05:37 UTC. This page is informational and not investment advice.